COMMUNIQUÉS West-GlobeNewswire

Alignment Health Unveils 2026 Medicare Advantage Plans with Strong Benefits, Expanded Support for Seniors
01/10/2025
Plans to reach nearly 8.3 million Medicare-eligible adults across five states during annual enrollment period, Oct. 15-Dec. 7 ORANGE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Alignment Health Plan , an award-winning [...]
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
01/10/2025
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, [...]
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
01/10/2025
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
01/10/2025
Appointments expand clinical and regulatory capabilities ahead of key program milestones BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on the [...]
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
01/10/2025
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that [...]
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
01/10/2025
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of [...]
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
01/10/2025
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
01/10/2025
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food [...]
CorVista Health Appoints Guido Neels and Dino Trevisani to Board of Directors
01/10/2025
Veteran MedTech leader Guido Neels joins CorVista, leveraging his experience as EW Healthcare Partners Operating Partner and former Guidant COO. Company founder Dino Trevisani returns to CorVista, bringing decades of [...]
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
01/10/2025
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead of the protocol-planned dose of 40mCi SYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics ( [...]
Stryker to announce financial results for its third quarter of fiscal year 2025
01/10/2025
Portage, Michigan, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its third quarter of fiscal year 2025 on Thursday, October 30, 2025. A press release will be [...]
ATMA CENA Grows National Mental Health Network to 13 Clinics
01/10/2025
Expanding access to safe, regulated psychedelic-assisted therapy across Canada CALGARY, Alberta, Oct. 01, 2025 (GLOBE NEWSWIRE) -- ATMA CENA, a Canadian mental health company specializing in psychedelic-assisted therapy [...]
Solid Biosciences to Present at Upcoming Scientific Meetings
01/10/2025
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from [...]
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
01/10/2025
- Meeting date aligns with prior guidance - - FDA to review AEON’s analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: [...]
SRx Health Solutions Appoints Joshua Epstein to Board of Directors and Compensation Committee
01/10/2025
TAMPA, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the appointment of Joshua Epstein to the Board of Directors and Compensation Committee. [...]
Sanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025
01/10/2025
FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2025
CLEVELAND, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
01/10/2025
BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented [...]
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
01/10/2025
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U.S. government [...]

Pages